Tempest Therapeutics Inc (TPST)

Ready to Jump After Recent Trade: Tempest Therapeutics Inc (TPST) – Sete News - SETE News

SETE News

Ratios in Focus: Analyzing Tempest Therapeutics Inc (TPST)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

The Dwinnex

Ratios in Focus: Analyzing Tempest Therapeutics Inc (TPST)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

The Dwinnex

A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) – US Post News - US Post News

US Post News

William Blair Equities Analysts Decrease Earnings Estimates for Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Defense World

Tempest Therapeutics (NASDAQ:TPST) Given Overweight Rating at Piper Sandler - Defense World

Defense World

Market cap of Tempest Therapeutics Inc [TPST] reaches 44.66M – now what? – The DBT News - The DBT News

The DBT News

Tempest Therapeutics (NASDAQ:TPST) Given Buy Rating at HC Wainwright - Defense World

Defense World

In the Green: Tempest Therapeutics Inc (TPST) Closes at 2.01, Up/Down -29.47 from Previous Day – DWinneX - The Dwinnex

The Dwinnex

Tempest Therapeutics (NASDAQ:TPST) Given Buy Rating at HC Wainwright - Defense World

Defense World

The TPST Stock Puzzle: Unraveling Tempest Therapeutics Inc’s Fluctuating Performance - The InvestChronicle

The InvestChronicle

Tempest stock falls after trial data for liver cancer drug (NASDAQ:TPST) - Seeking Alpha

Seeking Alpha

Tempest Flounders on News of Test Results - Baystreet.ca

Baystreet.ca

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday? - Tempest Therapeutics (NASDAQ ... - Benzinga

Benzinga

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a ... - GlobeNewswire

GlobeNewswire

Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? - InvestorPlace

InvestorPlace

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a ... - StockTitan

StockTitan

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace

InvestorPlace

Tempest Therapeutics Inc (TPST) stock analysis: A simple moving average approach – US Post News - US Post News

US Post News

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line ... - GlobeNewswire

GlobeNewswire

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line ... - StockTitan

StockTitan

Take off with Tempest Therapeutics Inc (TPST): Get ready for trading – Sete News - SETE News

SETE News

Tempest Therapeutics Inc Inc. (TPST) Price Performance: The Role of Supply and Demand - The InvestChronicle

The InvestChronicle

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Yahoo Finance

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Yahoo Finance

Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 2.1% - MarketBeat

MarketBeat

Tempest Therapeutics (NASDAQ:TPST) Trading Down 2.1% - MarketBeat

MarketBeat

Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 2.1% - MarketBeat

MarketBeat

Tempest Therapeutics (NASDAQ:TPST) Trading Down 2.1% - Defense World

Defense World

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) - Business Wire

Business Wire

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) - Business Wire

Business Wire

Get in on Tempest Therapeutics Inc's (TPST) buy-in window today! – Sete News - SETE News

SETE News

Tempest to Participate in Upcoming Investor Conferences - Yahoo Finance

Yahoo Finance

Tempest to Participate in Upcoming Investor Conferences - Yahoo Finance

Yahoo Finance

Short Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Increases By 39.8% - MarketBeat

MarketBeat

Short Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Increases By 39.8% - MarketBeat

MarketBeat

Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

MarketBeat

Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

MarketBeat

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Inc.

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

Yahoo Finance

Tempest Therapeutics (NASDAQ:TPST) Stock Price Up 1.1% - Defense World

Defense World

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire

The Tempest Therapeutics Inc (TPST) had a good session last reading, didn't it? – US Post News - US Post News

US Post News

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST) - Seeking Alpha

Seeking Alpha

Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now - Yahoo Movies UK

Yahoo Movies UK

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting - GlobeNewswire

GlobeNewswire

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting - Yahoo Finance

Yahoo Finance

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga